Altimmune Reports the P-IIb (IMPACT) Trial Data on Pemvidutide for Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Why It Matters

The findings demonstrate pemvidutide’s potential to address both liver pathology and systemic metabolic risk factors, positioning it as a differentiated candidate in a market hungry for effective MASH therapies. Success could reshape treatment algorithms and capture significant commercial value in the growing NAFLD/NASH space.

Key Takeaways

• Pemvidutide 1.8 mg cut triglycerides 23.7% in 48 weeks.
• Patients lost 7.5% body weight, BMI down 3 kg/m².
• Cholesterol fell 15.4%; waist circumference reduced 5.3 cm.
• Phase‑III MASH trial slated for H2 2026; alcohol trials due Q3 2026.

Pulse Analysis

Metabolic dysfunction‑associated steatohepatitis, commonly known as MASH or NASH, affects an estimated 25 million Americans and remains one of the few liver diseases without an approved therapy. The condition intertwines hepatic inflammation with systemic metabolic derangements such as dyslipidemia, obesity, and hypertension, driving a high unmet medical need for agents that can simultaneously target liver fibrosis and broader cardiometabolic risk. Pemvidutide, a dual GLP‑1 and GIP receptor agonist, leverages the proven weight‑loss and glycemic benefits of the GLP‑1 class while adding GIP‑mediated lipid modulation, making it a compelling candidate for this multifaceted disease.

In the IMPACT Phase‑IIb trial, 212 participants with F2‑F3 fibrosis received weekly subcutaneous pemvidutide at 1.2 mg or 1.8 mg doses versus placebo. The higher dose delivered striking metabolic improvements: triglycerides dropped 23.7%, total cholesterol fell 15.4%, systolic blood pressure decreased by 4 mmHg, and patients shed an average of 7.5% of body weight without hitting a plateau. These outcomes suggest that pemvidutide not only tackles hepatic injury but also mitigates the cardiovascular sequelae that often accompany MASH, a dual benefit that could differentiate it from other pipeline agents focused solely on liver endpoints.

Looking ahead, Altimmune’s roadmap includes a Phase‑III PERFORMA trial slated for the second half of 2026, aiming to confirm histologic resolution of fibrosis and steatohepatitis. Parallel studies—RECLAIM for alcohol‑use disorder and RESTORE for alcohol‑associated liver disease—are expected to report topline data by Q3 2026, expanding the drug’s potential indications. If Phase‑III results echo the Phase‑IIb signal, pemvidutide could capture a sizable share of the projected $30 billion NAFLD/NASH market, prompting strategic partnerships or acquisition interest from larger pharmaceutical players seeking to bolster their metabolic‑liver portfolios.